Does Rallies show Form 4 insider transactions for IBIO?

Yes. Rallies tracks IBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IBIO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IBIO. It does not provide personalized investment advice.

IBIO (iBio, Inc. Common Stock) Stock Analysis - Insider Trades

iBio, Inc. Common Stock (IBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, IBIO trades at $1.71 with a market cap of $70.54M and a P/E ratio of -3.01. IBIO moved +14.67% today. Year to date, IBIO is -9.57%; over the trailing twelve months it is +107.11%. Its 52-week range spans $0.56 to $6.89. Analyst consensus is strong buy with an average price target of $5.80. Rallies surfaces IBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IBIO stock inside the company?

Recent IBIO insider activity includes Banjak Marc bought 12.50K, Banjak Marc bought 1.43K, Duran Felipe bought 24.84K, Brenner Martin bought 12.34K, and Duran Felipe bought 9.19K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IBIO Key Metrics

Key financial metrics for IBIO
Metric	Value
Price	$1.71
Market Cap	$70.54M
P/E Ratio	-3.01
EPS	$-0.56
Dividend Yield	0.00%
52-Week High	$6.89
52-Week Low	$0.56
Volume	1.19K
Avg Volume	0
Revenue (TTM)	$300.00K
Net Income	$-27.61M
Gross Margin	0.00%

Recent IBIO Insider Trades

Banjak Marc bought 12.50K (~$20.53K) on Mar 26, 2026.
Banjak Marc bought 1.43K (~$2.52K) on Mar 26, 2026.
Duran Felipe bought 24.84K (~$50.13K) on Mar 19, 2026.
Brenner Martin bought 12.34K (~$24.92K) on Mar 19, 2026.
Duran Felipe bought 9.19K (~$25.00K) on Jan 10, 2025.

Latest IBIO News

iBio Secures Phase 1 IBIO-600 Clearance, IBIO-610 Cuts Visceral Fat by 6.7% — May 12, 2026
iBio Names Elizabeth Stoner to Board, Adds Biotech R&D Leader to Compensation Committee — May 8, 2026
iBio Gains Australia Clearance for IBIO-600 Phase 1 Trial, Dosing Q2 2026 — Apr 8, 2026
iBio to Name Optimized PH-HFpEF Bispecific Antibody Candidate by Q3 2026 — Mar 16, 2026
iBio’s IBIO-610 Cuts 6.7% Visceral, 5.2% Total Fat Mass and Shows 33-Day Half-Life — Mar 9, 2026

IBIO Analyst Consensus

5 analysts cover IBIO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.80.

Common questions about IBIO

Who is trading IBIO stock inside the company?: Recent IBIO insider activity includes Banjak Marc bought 12.50K, Banjak Marc bought 1.43K, Duran Felipe bought 24.84K, Brenner Martin bought 12.34K, and Duran Felipe bought 9.19K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IBIO?: Yes. Rallies tracks IBIO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IBIO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IBIO. It does not provide personalized investment advice.